|CardioPharma, Inc. is focused on the global development of combinatorial cardiovascular products. The company's pipeline is cardiovascular disease – pharmaco-economic-centric - designing products to be highly cost-effective, targeting reduced expenditures at all levels, with proven efficacy, and providing both patient and provider convenience in order to minimize what has become an epic problem throughout healthcare: compliance. At CardioPharma, we believe our products are in the right place at the right time!
||While CardiaPill®, the lead product of CardioPharma, broadly targets cardiovascular disease, pipeline products focus on specific cardiovascular disease patient populations, such as metabolic syndrome and Lupus. The company's pipeline is backed by intellectual property that has issued in the US, EU and other international markets. CardioPharma believes that additional anticipated patents will further strengthen our company’s future.